Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Secondary Prophylaxis of CIT in Breast Cancer
NCT07771881Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Aug 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
A Phase 2 trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Fudan University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT07771881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07771881.